5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Drug Class (Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, and Others) and Geography
Fastest Growing Market:
Antiretroviral are the drugs that treat HIV. Factors contributing to the growth of the market includes rising burden of HIV, increasing investment in R&D and increase in availability of novel drugs with better efficacy. According to the U.S. Department of Health & Human Services, there were approximately 37.9 million people worldwide that were living with HIV/AIDS. An estimated 1.7 million individuals worldwide became newly infected with HIV in 2018. Anti-retrovirals (ARVs) are the foundation of HIV/AIDS management, as currently there is no cure or vaccine available for HIV. In individuals with a non-resistant strain of HIV, the antiretroviral treatment can suppress the replication of HIV in about 80% of cases. This huge patient pool shows that the market for anti-retroviral drugs is expected to grow in the forecast period.
As per the scope of the report, Anti-retroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. A retrovirus is a group of virus that belongs to the family Retroviridae and they characteristically carry their genetic blueprint in the form of ribonucleic acid (RNA). The anti-retroviral drugs hinder the multiplication of these viruses rather than killing them.
|By Drug Class|
|Multi-class Combination Products|
|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|
|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)|
Report scope can be customized per your requirements. Click here.
Based on drug class, it is segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Others. The key factor contributing to the growth of the Multi-class Combination Products is the rising burden of HIV and new drug approval. According to WHO, around 770,000 people died from HIV in 2018. Many companies are focusing on developing breakthrough products for the treatment of antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets. Additionally, the increase in funding for companies involved in the research related to anti-retroviral drugs is expected to boost the studied market.
To understand key trends, Download Sample Report
The Anti-retroviral Drugs market holds the largest share in the North America region. According to the U.S. Department of Health & Human Services, it is estimated that there are over 56,000 new cases of HIV in the United States each year and about 20 in 100 infected Americans do not know they have the virus. The growth is attributed to a high ART coverage rate and rising emphasis on prescribed branded drugs. In addition, the National Institutes of Health (NIH), United States, represents the largest public investment in HIV/AIDS research in the world, which is expected to fuel the market growth.
To understand geography trends, Download Sample Report.
The present demand of companies in the anti-retroviral segment is improving upon its research and development capabilities via collaboration, merger, and acquisition, as well as exploring new geographic regions. The global players in the anti-retroviral drugs market are - AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Merck & Co, Inc., Mylan N.V., and ViiV Healthcare.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of HIV
4.2.2 Increasing Investment in R&D
4.2.3 Increase in Availability of Novel Drugs with Better Efficacy
4.3 Market Restraints
4.3.1 Side Effects of Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Protease Inhibitors
5.1.2 Integrase Inhibitors
5.1.3 Multi-class Combination Products
5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.2.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Bristol-Myers Squibb Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Gilead Sciences, Inc.
6.1.6 Merck & Co, Inc.
6.1.7 Mylan N.V.
6.1.8 ViiV Healthcare
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments